Metastatic and high-risk localized prostate cancer respond to hormone therapy but outcomes vary. Following a pre-specified statistical plan, we used Cox models adjusted for clinical variables to test associations with survival of multi-gene expression-based classifiers from 781 patients randomized to androgen deprivation with or without abiraterone in the STAMPEDE trial. Decipher score was strongly prognostic (p<2x10 -5 ) and identified clinically-relevant differences in absolute benefit, especially for localized cancers. In metastatic disease, classifiers of proliferation, PTEN or TP53 loss and treatment-persistent cells were prognostic. In localized disease, androgen receptor activity was protective whilst interferon signaling (that strongly associated with tumor lymphocyte infiltration) was detrimental. Post-Operative Radiation-Therapy Outcomes Score was prognostic in localized but not metastatic disease (interaction p=0.0001) suggesting the impact of tumor biology on clinical outcome is context-dependent on metastatic state. Transcriptome-wide testing has clinical utility for advanced prostate cancer and identified worse outcomes for localized cancers with tumor-promoting inflammation.
Research square. 2023 Feb 08*** epublish ***
Gerhardt Attard, Marina Parry, Emily Grist, Larissa Mendes, Peter Dutey-Magni, Ashwin Sachdeva, Christopher Brawley, Laura Murphy, James Proudfoot, Sharanpreet Lall, Yang Liu, Stefanie Friedrich, Mazlina Ismail, Alex Hoyle, Adnan Ali, Aine Haran, Anna Wingate, Leila Zakka, Daniel Wetterskog, Claire Amos, Nafisah Atako, Victoria Wang, Hannah Rush, Robert Jones, Hing Leung, William Cross, Silke Gillessen, Chris Parker, Simon Chowdhury, Tamara Lotan, Teresa Marafioti, Alfonso Urbanucci, Edward Schaeffer, Daniel Spratt, David Waugh, Thomas Powles, Daniel Berney, Matthew Sydes, Mahesh Parmar, Anis Hamid, Felix Feng, Christopher Sweeney, Elai Davicioni, Noel Clarke, Nicholas James, Louise Brown